Google article title if interested in full story, "Deutsche Bank Increases Neurocrine Biosciences Price Target to $25.00 (NBIX)"
Over the next 12 months we see four key catalysts that will provide upside to Neurocrine shares: Kinect Ph2, Kinect2 Ph2, Kinect safety, & Elagolix ph3 topline results. We also believe the opportunity for Elagolix in uterine fibroids (UF) is underappreciated. We have increased our probabilities for Elagolix in endometriosis (75% to 85%), VMAT2 (25% to 50%) to reflect trialsuccesses over next 12 mo & raised Elagolix UF estimates. Maintain Buy.,” Deutsche Bank’s analyst commented.